Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46405

1.

Temporal auto-regulation during human PU.1 locus SubTAD formation.

Schuetzmann D, Walter C, van Riel B, Kruse S, König T, Erdmann T, Tönges A, Bindels E, Weilemann A, Gebhard C, Wethmar K, Perrod C, Minderjahn J, Rehli M, Delwel R, Lenz G, Gröschel S, Dugas M, Rosenbauer F.

Blood. 2018 Oct 12. pii: blood-2018-02-834721. doi: 10.1182/blood-2018-02-834721. [Epub ahead of print]

PMID:
30315124
2.

Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.

Khandelwal S, Ravi J, Rauova L, Johnson A, Lee GM, Gilner JB, Gunti S, Notkins AL, Kuchibhatla M, Frank M, Poncz M, Cines DB, Arepally GM.

Blood. 2018 Oct 11. pii: blood-2018-03-834598. doi: 10.1182/blood-2018-03-834598. [Epub ahead of print]

PMID:
30309891
3.

Spotlight on: reversing anti factor Xa agents and the unmet needs in trauma patients.

Hunt BJ, Neal MD, Stensballe J.

Blood. 2018 Oct 11. pii: blood-2018-06-850396. doi: 10.1182/blood-2018-06-850396. [Epub ahead of print]

PMID:
30309890
4.

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.

Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, Le Gouill S, Touzeau C, Moreau P, Pellat-Deceunynck C, Amiot M.

Blood. 2018 Oct 11. pii: blood-2018-03-836718. doi: 10.1182/blood-2018-03-836718. [Epub ahead of print]

PMID:
30309889
5.

Hyperviscosity syndrome in splenic marginal zone lymphoma.

Daniel R, Chan RY.

Blood. 2018 Oct 11;132(15):1627. doi: 10.1182/blood-2018-07-863787. No abstract available.

PMID:
30309878
6.

Patchy hematopoiesis mimicking bone metastasis.

Cornelisse AC, Te Boekhorst PAW.

Blood. 2018 Oct 11;132(15):1626. doi: 10.1182/blood-2018-06-856823. No abstract available.

PMID:
30309877
7.

Brain iron in sickle cell disease?

Kirkham FJ, Shmueli K.

Blood. 2018 Oct 11;132(15):1550-1552. doi: 10.1182/blood-2018-08-867010. No abstract available.

PMID:
30309876
8.

Three strikes to a hemophilic joint bleed.

Lisman T.

Blood. 2018 Oct 11;132(15):1548-1550. doi: 10.1182/blood-2018-08-865626. No abstract available.

PMID:
30309875
9.

A new triple threat to CLL.

Lampson BL, Davids MS.

Blood. 2018 Oct 11;132(15):1547-1548. doi: 10.1182/blood-2018-08-870808. No abstract available.

PMID:
30309874
10.

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.

Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U.

Blood. 2018 Oct 10. pii: blood-2018-06-855221. doi: 10.1182/blood-2018-06-855221. [Epub ahead of print]

PMID:
30305280
11.

Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor.

Xu ER, von Bülow S, Chen PC, Lenting PJ, Kolšek K, Aponte-Santamaría C, Simon B, Foot J, Obser T, Schneppenheim R, Gräter F, Denis CV, Wilmanns M, Hennig J.

Blood. 2018 Oct 10. pii: blood-2018-04-843615. doi: 10.1182/blood-2018-04-843615. [Epub ahead of print]

PMID:
30305279
12.

Inflammatory signals directly instruct PU.1 in HSCs via TNF.

Etzrodt M, Ahmed N, Hoppe PS, Loeffler D, Skylaki S, Hilsenbeck O, Kokkaliaris KD, Kaltenbach HM, Stelling J, Nerlov C, Schroeder T.

Blood. 2018 Oct 9. pii: blood-2018-02-832998. doi: 10.1182/blood-2018-02-832998. [Epub ahead of print]

PMID:
30301719
13.

The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL.

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.

Blood. 2018 Oct 4. pii: blood-2018-05-850461. doi: 10.1182/blood-2018-05-850461. [Epub ahead of print]

PMID:
30287523
14.

An unexpected association of hematologic malignancies.

Athanase N, Frébet E.

Blood. 2018 Oct 4;132(14):1545. doi: 10.1182/blood-2018-03-842013. No abstract available.

PMID:
30287471
15.

Mice no longer immune to immunomodulatory drugs.

Pichiorri F.

Blood. 2018 Oct 4;132(14):1470-1471. doi: 10.1182/blood-2018-08-868083. No abstract available.

PMID:
30287470
16.

MBD4: guardian of the epigenetic galaxy.

Busque L, Godley LA.

Blood. 2018 Oct 4;132(14):1468-1469. doi: 10.1182/blood-2018-08-867044. No abstract available.

PMID:
30287469
17.

Getting the most from your CAR target.

Barrett DM.

Blood. 2018 Oct 4;132(14):1467-1468. doi: 10.1182/blood-2018-08-869552. No abstract available.

PMID:
30287468
18.

Next-generation therapy for follicular lymphoma.

Nastoupil LJ.

Blood. 2018 Oct 4;132(14):1465-1467. doi: 10.1182/blood-2018-08-868117. No abstract available.

PMID:
30287467
19.

M-protein-related disorders: MGCS.

Bladé J, Cibeira MT.

Blood. 2018 Oct 4;132(14):1464-1465. doi: 10.1182/blood-2018-07-865642. No abstract available.

PMID:
30287466
20.

A long sought after "receptor" for ERFE?

Zhang AS, Enns CA.

Blood. 2018 Oct 4;132(14):1463-1464. doi: 10.1182/blood-2018-08-869586. No abstract available.

PMID:
30287465

Supplemental Content

Loading ...
Support Center